- Home
- HOOK vs NCRA Comparison
HOOK vs NCRA Comparison
Compare HOOK & NCRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- NCRA
- Stock Information
- Founded
- HOOK 2011
- NCRA 2002
- Country
- HOOK United States
- NCRA Taiwan
- Employees
- HOOK N/A
- NCRA N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- NCRA Farming/Seeds/Milling
- Sector
- HOOK Health Care
- NCRA Consumer Staples
- Exchange
- HOOK Nasdaq
- NCRA Nasdaq
- Market Cap
- HOOK 9.3M
- NCRA 13.9M
- IPO Year
- HOOK 2019
- NCRA N/A
- Fundamental
- Price
- HOOK $1.47
- NCRA $0.91
- Analyst Decision
- HOOK Buy
- NCRA
- Analyst Count
- HOOK 4
- NCRA 0
- Target Price
- HOOK $10.67
- NCRA N/A
- AVG Volume (30 Days)
- HOOK 134.3K
- NCRA 71.0K
- Earning Date
- HOOK 05-20-2025
- NCRA 05-14-2025
- Dividend Yield
- HOOK N/A
- NCRA N/A
- EPS Growth
- HOOK N/A
- NCRA N/A
- EPS
- HOOK N/A
- NCRA N/A
- Revenue
- HOOK $43,946,000.00
- NCRA $17,013,132.00
- Revenue This Year
- HOOK N/A
- NCRA N/A
- Revenue Next Year
- HOOK N/A
- NCRA N/A
- P/E Ratio
- HOOK N/A
- NCRA N/A
- Revenue Growth
- HOOK 118.32
- NCRA N/A
- 52 Week Low
- HOOK $0.72
- NCRA $0.70
- 52 Week High
- HOOK $10.50
- NCRA $2.09
- Technical
- Relative Strength Index (RSI)
- HOOK 67.61
- NCRA 47.81
- Support Level
- HOOK $1.14
- NCRA $0.78
- Resistance Level
- HOOK $1.67
- NCRA $1.20
- Average True Range (ATR)
- HOOK 0.16
- NCRA 0.11
- MACD
- HOOK 0.10
- NCRA -0.00
- Stochastic Oscillator
- HOOK 78.69
- NCRA 30.98
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with expert consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.